118 related articles for article (PubMed ID: 1505150)
1. Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans.
Billah MM; Gilchrest HG; Eckel SP; Granzow CA; Lawton PJ; Radwanski E; Brannan MD; Affrime MB; Christopher JD; Richards W
Clin Pharmacol Ther; 1992 Aug; 52(2):151-9. PubMed ID: 1505150
[TBL] [Abstract][Full Text] [Related]
2. Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine.
Billah MM; Chapman RW; Egan RW; Gilchrest H; Piwinski JJ; Sherwood J; Siegel MI; West RE; Kreutner W
J Pharmacol Exp Ther; 1990 Mar; 252(3):1090-6. PubMed ID: 2319461
[TBL] [Abstract][Full Text] [Related]
3. Discovery and preliminary pharmacology of Sch 37370, a dual antagonist of PAF and histamine.
Billah MM; Egan RW; Ganguly AK; Green MJ; Kreutner W; Piwinski JJ; Siegel MI; Villani FJ; Wong JK
Lipids; 1991 Dec; 26(12):1172-4. PubMed ID: 1819703
[TBL] [Abstract][Full Text] [Related]
4. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine.
Billah MM; Chapman RW; Watnick AS; Egan RW; Siegel MI; Kreutner W
Agents Actions Suppl; 1991; 34():313-21. PubMed ID: 1793070
[TBL] [Abstract][Full Text] [Related]
5. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
6. Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine.
Kaminski JJ; Carruthers NI; Wong SC; Chan TM; Billah MM; Tozzi S; McPhail AT
Bioorg Med Chem; 1999 Jul; 7(7):1413-23. PubMed ID: 10465415
[TBL] [Abstract][Full Text] [Related]
7. Determination of plasma concentrations of SCH 44643 by a GC method and correlation of plasma concentration and anti-PAF activity in cynomolgus monkeys.
Lin CC; Billah M; Kim HK; Egan R; Anthes J; Gilchrest H; Cayen M
J Pharm Biomed Anal; 1996 Dec; 15(3):343-7. PubMed ID: 8951694
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine.
Barnett A; Iorio LC; Kreutner W; Tozzi S; Ahn HS; Gulbenkian A
Agents Actions; 1984 Jun; 14(5-6):590-7. PubMed ID: 6236679
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous platelet-activating factor (PAF) receptors and calcium increase in platelets and macrophages.
Centemeri C; Colli S; Tosarello D; Ciceri P; Nicosia S
Biochem Pharmacol; 1999 Feb; 57(3):263-71. PubMed ID: 9890553
[TBL] [Abstract][Full Text] [Related]
10. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
Carceller E; Merlos M; Giral M; Balsa D; Almansa C; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1994 Aug; 37(17):2697-703. PubMed ID: 7914928
[TBL] [Abstract][Full Text] [Related]
11. Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
Piwinski JJ; Wong JK; Green MJ; Ganguly AK; Billah MM; West RE; Kreutner W
J Med Chem; 1991 Jan; 34(1):457-61. PubMed ID: 1671420
[No Abstract] [Full Text] [Related]
12. Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin.
Sansom JE; Brooks J; Burton JL; Archer CB
Clin Exp Dermatol; 1996 Jan; 21(1):33-7. PubMed ID: 8689766
[TBL] [Abstract][Full Text] [Related]
13. Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.
Piwinski JJ; Wong JK; Green MJ; Kaminski JJ; Colizzo F; Albanese MM; Ganguly AK; Billah MM; Anthes JC; West RE
Bioorg Med Chem Lett; 1998 Dec; 8(24):3469-74. PubMed ID: 9934454
[TBL] [Abstract][Full Text] [Related]
14. Consumption of plant extract supplement reduces platelet activating factor-induced platelet aggregation and increases platelet activating factor catabolism: a randomised, double-blind and placebo-controlled trial.
Gavriil L; Detopoulou M; Petsini F; Antonopoulou S; Fragopoulou E
Br J Nutr; 2019 May; 121(9):982-991. PubMed ID: 30940217
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
16. (Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
Carceller E; Almansa C; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1992 Oct; 35(22):4118-34. PubMed ID: 1433215
[TBL] [Abstract][Full Text] [Related]
17. Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro.
Lohde C; Bahr T; Labes D; Grupe R
Arzneimittelforschung; 1992 Jan; 42(1):27-31. PubMed ID: 1375025
[TBL] [Abstract][Full Text] [Related]
18. Terfenadine effect on the bronchoconstriction, dermal response, and leukopenia induced by platelet-activating factor.
Hopp RJ; Townley RG; Agrawal DK; Bewtra AK
Chest; 1991 Oct; 100(4):994-8. PubMed ID: 1914619
[TBL] [Abstract][Full Text] [Related]
19. Interaction studies in mice of SCH 29851, a potential non-sedating antihistamine, with commonly used therapeutic agents.
Iorio LC; Cohen-Winston M; Barnett A
Agents Actions; 1986 Aug; 18(5-6):485-93. PubMed ID: 2945410
[TBL] [Abstract][Full Text] [Related]
20. Rupatadine, a dual antagonist of histamine and platelet-activating factor (PAF), attenuates experimentally induced diabetic nephropathy in rats.
Hafez HM; Abdel-Hakeem EA; Hassanein H
Naunyn Schmiedebergs Arch Pharmacol; 2020 Aug; 393(8):1487-1500. PubMed ID: 32200462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
